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Role of cGMP as second messenger of adenosine in the inhibition of
renin release. Adenosine is known to be a potent inhibitor of renin
release from the kidneys. The aim of this study was to investigate the
transmembrane signalling avenue that the second messenger of adeno-
sine causes inhibition of renal renin release. Using short term cultures
of juxtaglomerular cells isolated from rat kidneys, we found that
adenosine inhibited spontaneous renin release from these cells up to
40% of control, in a dose dependent fashion between 10—10 M to 10_6 M.
Half maximal inhibition was observed at 2 x 10_8 M adenosine. The
inhibitory effect of adenosine on renin release could be mimicked by the
A1-receptor agonist N6-cyclohexyladenosine (CHA) and could be at-
tenuated by the A-receptor antagonist theophylline (5 X l0 M). The
A2-receptor agonist 5'-N-ethylcarboxamideadenosine (NECA) had no
inhibitory effect on renin release. These findings indicate that the
inhibitory effect of adenosine is mediated by A1-receptors onjuxtaglo-
merular cells. Adenosine had no effect on either transmembrane cal-
cium influx or the cytosolic free calcium concentration in the isolated
juxtaglomerular cells. Adenosine also did not alter the cellular level of
cyclic AMP in the concentration range employed. However, adenosine
led to a dose dependent increase of the cellular level of cyclic GMP.
Half maximal increase of cGMP was observed at lO M adenosine. The
effect of adenosine on cyclic GMP could be mimicked by the A1-
receptor agonist CHA and could be attenuated by the A-receptor
antagonist, theophylline. We infer from our results that inhibition of
renin release by adenosine could be mediated by an A1-receptor linked
rise of cGMP in renal juxtaglomerular cells. This conclusion is sup-
ported by our previous finding that cGMP is an inhibitory signal for
renin release from renal juxtaglomerular cells.
Intrarenal infusion of adenosine (ado) has been found to
strongly inhibit renin release from the kidneys [1—3]. There is
good evidence obtained from whole kidney experiments that
this effect of ado on renin release is not mediated by either the
baroreceptor or the macula densa receptor [4], suggesting a
direct interaction between ado and juxtaglomerular cells. This
conclusion is confirmed by the finding that ado also inhibits
renin release from renal cortical slices [5, 6], isolated afferent
arterioles [7], and isolated glomeruli [61. The demonstration of
a direct interaction between ado and juxtaglomerular cells is,
however, lacking so far. Furthermore, there is experimental
evidence that the inhibitory effect of ado on renin release is
mediated by cell surface receptors of the A1-subclass [5, 7, 81.
However, the mechanism by which occupancy of adenosine
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receptors leads to an inhibition of renin release from juxtaglo-
merular cells has not been clarified so far.
There is good evidence to indicate that renin release from
juxtaglomerular cells is affected by the intracellular concentra-
tions of calcium and of cyclic nucleotides in a way that calcium
[9, 10] and cGMP [111 act as inhibitory signals, while cAMP is
a stimulatory signal [9, 10]. A substance that inhibits renin
release, such as ado, could therefore do so by either raising the
concentrations of calcium or cGMP, or by lowering the con-
centration of cAMP within juxtaglomerular cells. We have
recently developed a method that permits an establishment of
reproducible, short-term cell cultures containing around 90%
juxtaglomerular cells [II]. Moreover, we have shown that this
cell culture model is suitable for the study of renin release on a
cellular level [11—131.
Using such juxtaglomerular cells isolated from rat kidneys we
investigated the effects of ado on renin release, transmembrane
calcium influx, cytosolic free calcium concentration and intra-
cellular levels of cAMP and cGMP.
We found that ado inhibits renin release from juxtaglomerular




Short-term cultures of rat renal juxtaglomerular cells were
made as described previously. In brief, a single cell suspension
was prepared by kidney perfusion with citrate, enzymatical
dissociation with trypsin and collagenase, and sieving over a 22
im screen exactly as described [13]. This single cell suspension
was then further separated on a 25% isoosmotic percoll gradient
and cells with a density of 1.06 g/ml were used for culture. For
a typical isolation procedure the kidneys of a single rat were
used. They gave a yield of around 40 million single cells and
were mixed with 4 x 30 ml 25% isoosmotic percoll. From the
four gradients a total of around 3 million cells were harvested
from the bands with a density of 1.06 g/ml. For experiments to
determine renin secretion, iO cells were seeded per 7 cm2 dish;
for experiments to determine cyclic nucleotides 3 x l0 cells
were seeded per dish. On the second day of culture around
between 20 to 30% of the seeded cells were attached, and
around 90% of the attached cells were juxtaglomerular cells as
judged from the specific immunostaining for rat renin [11].
Experiments with the cells were done two days after seeding as
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a rule. Distribution of renin containing cells was determined in
every third cell preparation with indirect immunofluorescence
staining as described in [13].
Renin release
Determination of renin release from the cultured cells was
done exactly as described in [12] by measuring the linear
increase of renin activity of the cell supernatant 10, 20 and 30
minutes after onset of the experiments. In brief, the culture
medium was replaced with prewarmed, Hepes buffered saline
(132 mt NaCI, 5 mivi KCI, 0.8 mrvi MgSO4, 2 mri CaCl2, 10 mM
NaOAc, 2 mi NaH2PO4, 10 m glucose, 20 mM Hepes, pH
7.2). The culture dishes were placed on a heating block at 37°C,
and the time dependent increase of the renin activity of the
buffer was monitored. Renin activity was determined by its
ability to generate angiotensin I from the plasma of bilaterally
nephrectomized rats as described in [14]. Angiotensin I was
measured with a commercially available radioimmunoassay
(Isotopen Dienst West, Teufen, Switzerland).
Intracellular contents of cAMP and cGMP
Intracellular levels of cyclic nucleotides were examined un-
der the same experimental conditions as the renin release. In
brief, five minutes after onset of the experiments the buffer was
removed from the cells, and the dishes were placed on an ice
block. After the addition of 0.4 ml of ice-cold buffer (5 mM
potassium phosphate, 0.2 mM EDTA, 0.5 mM 3-isobutyl-meth-
ylxanthine and ISO mt KCI, pH 6.8), the cells were scraped off
with a teflon policeman. The cell suspension so obtained was
sonicated, boiled for five minutes, and centrifuged. An aliquot
was removed from the sonicated cell suspension for protein
determination. The supernatants were assayed for cAMP and
cGMP using radioimmunoassays (New England Nuclear, Bos-
ton, Massachusetts, USA).
45Calcium-influx
45Ca-uptake into the cultured cells was determined as out-
lined in [12]. In brief, the culture medium was substituted by a
Hepes-buffered saline containing 2 pCi/mi 45Ca. Simultaneously
agents were added. After either 2, 5, 10 or 20 minutes the buffer
was withdrawn and the cells were quickly washed with 10 X I ml
ice-cold Krebs solution containing 10 mivi CaCI2. The cells were
lysed by the addition of I ml I N NaOH and the radioactivity
was counted with a 13-scintillation counter.
Intracellular Ca2 measurement
Intracellular Ca2, [Ca]1, was measured using quin-2. About 2
x l0 cells were incubated with 25 LM quin-2 AM [tetrakis
(acetoxymethyI)ester of quin-2] in RPMI 1640 for 20 minutes,
followed by another 40 minute incubation with 4 volumes of
medium. After the incubation period, aliquots of I x 106 cells
were washed twice and resuspended in Hepes-buffered saline.
Fluorescence of quin-2 loaded cells was measured at 37°C in a
Perkin-Elmer fluorescence spectrophotometer L93 using exci-
tation wavelength of 340 nm and emission wavelength of 490
nm. Each trace was monitored for at least five minutes. The
fluorescence signal was calibrated at the end of each individual
trace essentially as described by Tsien, Pozzan and Rink [15].
Cell numbers were determined with a Coulter counter.
Protein determination
Protein was determined according to the method of Lowry et
al [16] using bovine serum albumin as a standard. One mg of
cellular protein corresponds to around two million cells.
Statistics
Levels of significance were calculated utilizing Students
unpaired I-test. P < 0.05 was considered significant.
Reagents
All reagents for the culture medium were obtained from
Boehringer (Mannheim, FRG). Percoll was from Pharmacia
Diagnostics, Uppsala, Sweden). Adenosine, N6-cyclohexyl-
adenosine (CHA) and theophylline were purchased from Sigma
Chemical Co., St. Louis, Missouri, USA. 5'-N-ethylcarboxami-
deadenosine (NECA) was from Byk Gulden Company (Konstanz,
FRG). 45Ca was from Amersham (U.K.) and quin-2 AM was
obtained from Calbiochem.
Results
The effect of adenosine(ado) on the spontaneous renin release
from the isolated juxtaglomerular cells is shown in Figure 1.
Ado led to a dose dependent inhibition of renin release to
around 40% of control in a concentration range between l0 to
10—6 M. Half maximal inhibition was observed at 2 x I0_8 M. To
test whether or not the inhibitory effect of ado on renin release



















Fig. 1. Dependency of spontaneous renin release from the isolated
juxtaglo,nerular cells on the extracellular concentration of adenosine.
Data are mean s of 8 experiments. The vertical dashed line indicates
the concentration of adenosine required for half maximal effect. Aster-
isk indicates P < 0.05 vs. control.
















Control Theophylline Ado Ado 107M CHA NECA
5 x 105M 107M + 107M 107M
Theo 5105M
Fig. 2. Renin releasing rate from the isolated
juxtaglomerular cells in presence of adenosine
(1O— M), theophylline (5 x IO M), CHA (IO—
M) and NECA (1O— M). Data are mean SE.
Numbers at the bottom of the columns indicate
numbers of experiments. The dashed line indi-














Fig. 4. Dependency of intracellular levels of cAMP and cGMP in
isolated juxtaglomerular cells on the extracellular concentration of
adenosine. Data are mean Sr of ten experiments and are given as
percentage of the mean of the control value (= absence of adenosine).
Mean of controls were 460 fmol/mg protein for cAMP and 60 fmol/mg of
protein for cGMP. The horizontal dashed line indicates the mean of
control, the vertical dashed line indicates the concentration of adeno-
sine required for half maximal effect on cGMP. Asterisk indicates P <
0.05 vs. control.
Since the results obtained so far indicated that the inhibitory
effect of ado on renin release was mediated by cell surface
receptors of ado, the next set of experiments were designed to
identify possible intracellular messengers that might mediate
the effect of ado in juxtaglomerular cells.
0 10-10 io- ,_B io io-Time, mmFig. 3. Uptake of 45Ca into isolated juxtaglomerular cells in absence
and presence of adenosine (iO M) as a function of time. Data are
mean SEM of four experiments.
A-receptor antagonists and A-receptor agonists on renin release
was investigated. As shown in Figure 2, theophylline at a low
concentration (5x l0— M), considered to antagonize adenosine
A-receptor effects [17], alone did not significantly alter the
spontaneous renin release from the cells. However, it obviously
abolished the inhibitory effect of lO M ado. We further
investigated the effects of the A-receptor agonists [17] N6-
cyclohexyl adenosine(CHA) and 5'-ethylcarboxamide adeno-
sine(NECA) on renin release from the isolated juxtaglomerular
cells. As it can be seen in Figure 2, CHA (10—v M) but not
NECA (l0- M) mimicked the inhibitory effect of l0 M ado on
renin release.
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There is good experimental evidence that renin release is
inversely related to the intracellular concentration of calcium
[9, 10]. We therefore tested the effect of ado (l0- M) on both
transmembrane calcium influx and cytosolic free calcium in the
isolated juxtaglomerular cells. Using the 45Ca-tracer method,
45calcium uptake is shown in Figure 3. It is obvious that
adenosine did not enhance 45Ca-uptake by the cells. Cytosolic-
free calcium concentration as monitored with the quin-2 method
was 233 28 n (mean SE; N = 7) in the absence of ado and
231 9 nrvi (mean SE; N = 7) in the presence of ado. For
comparison angiotensin II (l0- M) caused an increase of Ca2t
to 529 7 nri (N = 5). Both results indicate that ado at a
concentration at which it maximally inhibited renin release did
not alter calcium influx or cytosolic free calcium. Cyclic nude-
otides such as cAMP [9, 101 and cGMP [11] are also considered
as second messengers that are involved in the intracellular
control of renin release. We therefore investigated the effects of
ado on the intracellular levels of cAMP and cGMP in the
juxtaglomerular cells. Figure 4 shows the cellular contents of
cAMP and cGMP five minutes after addition of adenosine. In
pilot experiments for this study, in which we determined cyclic
nucleotide levels after 2, S and 15 minutes, as well as in recent
studies [II, 12], a five minute interval was found as the best
time point for optimal agonist-induced changes of both cAMP
and cGMP. As it can be seen from Figure 4, ado did not affect
the intracellular level of cAMP in the concentration range
between i0 M to lO_6 M. On the other hand a dose dependent
increase of the level of cGMP was observed in this concentra-
tion range of ado. Half maximal increase of cGMP; was
achieved with 108 M ado.
Since we have recently shown that cGMP is an inhibitory
signal for renin release from isolated juxtaglomerular cells [II]
the question arises whether or not the inhibitory effect of ado on
renin release coud be explained by the rise of cGMP1. As
documented in Figure 2, the inhibitory effect of ado on renin
release could be attenuated by theophylline and could be
mimicked by CHA but not by NECA. Figure 5 shows the
intracellular cGMP levels under these experimental conditions.
It can be seen that theophylline itself did not significantly alter
cGMP1 but it abolished the rise in cGMP1 induced by ado. It is
furthermore evident that the effect of ado on cGMP could be
mimicked by CHA but not by NECA. We want to emphasize
here that none of the experimental conditions demonstrated in
Figure 5 led to any change in cAMP1 in the isolated juxtaglo-
merular cells. For comparison isoproterenol (l0— M) led to an
increase of cAMP1 to 346 65% of the control (N = 5).
To see whether the rise in cGMP1 induced by ado would be
sufficient to explain its inhibitory effect of renin release we
further compared the effects of ado on both renin release and
cGMP1 with a correlation between renin release and cGMP1 that
was obtained in a recent study [11]. This correlation is depicted
as a dotted line in Figure 6. Together with this line experimental
data obtained with ado (closed circles) and CHA (open circle)
are shown in this figure. It is evident from Figure 6 that the
experimental points obtained with ado and CHA fit very well to
the correlation between cGMP, and renin release which was
obtained from independent experiments.
Discussion
This study was designed to investigate by which way of
transmembrane signalling adenosine(ado) inhibits renal renin
release. Using a cell preparation highly enriched in juxtaglo-
merular cells we found that ado caused a dose dependent
inhibition of renin release from the cells (Fig. 1). This result
indicates that ado inhibits renin release by a direct action on
renal juxtaglomerular cells, and this result thus confirms the
conclusions drawn from experiments done with whole kidneys,
renal cortical slices [5, 6], isolated afferent arterioles [7], and
isolated glomeruli [6], which predicted a direct interaction
between ado and juxtaglomerular cells. We further found that
inhibition of renin release from juxtaglomerular cells by ado
was dose dependent in a concentration range between lO M to
lO_6 M, and half-maximal inhibition was observed at 2 X 10-8












Control Theophylline Ado Ado 107M CHA NECA
5x105M 107M + 107M 107M
Theo. 5x104M
Fig. 5. Intracellular levels of cGMP in isolated
juxtaglomerular cells in presence of adenosine
(IO M), theophylline (5 x io M), CHA (IO—
si) and NECA (1O M). Data are mean SE.
Numbers at the bottom of the columns indicate
the numbers of experiments. The dashed line
indicates the control value. Asterisk indicates P
<0.05 vs. control.
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Fig. 6. Relation between cellular levels of cGMP and renin release
from isolated juxtaglomerular cells in presence of ado (0 — 1O6 M)
(closed circles) and CHA (open circles). Renin releasing rate values are
taken from Figs. I and 2, and cGMP levels are taken from Figs. 3 and
4. Data are given as the percentage of the control value, which was
obtained in absence of ado and CHA. The dashed line is the last square
regression curve for a correlation between cGMP and renin releasing
rate obtained in a recent study in which atrial natriuretie peptide,
sodium nitroprusside, M&B 22948 and methylene blue were used in
order to vary cGMP [II].
Churchill obtained from experiments with renal cortical slices
[5]. Moreover our results indicate that the inhibitory effect of
ado on renin release is mediated by A1-cell surface receptors on
juxtaglomerular cells, because the effect of ado could be blocked
by the A-receptor antagonist theophylline [17] and could be
mimicked by the A1-receptor agonist CHA [17], but not by the
A2-receptor agonist NECA [171 (Fig. 2). Again these findings
fully confirm the results of experiments performed with whole
kidneys [8, 18], renal cortical slices [5] and isolated arteriols [7].
Under the assumption that the effect of ado is mediated by
A1-cell surface receptors on juxtaglomerular cells the question
arises about the intracellular second messenger that mediates
the effect of ado.
One candidate for such a second messenger role is calcium,
because calcium is known as an inhibitory intracellular signal
for renin release [9, 101. We therefore determined the effect of
ado at a concentration (l0 NI) that almost maximally inhibits
renin release (Fig. 1) on transmembrane calcium influx and on
the cytosolic-free calcium concentration. However, we failed to
detect any effect of ado on each of these parameters. The result
that ado did not enhance transmembrane calcium influx into the
juxtaglomerular cells complements reports on the lack of effect
of calcium channel blockers on the inhibition of renin release
caused by ado [4, 5, 191 in whole kidneys [4, 19] and renal
cortical slices [5]. The entirety of these results indicate that
inhibition of renin release is not caused by an enhanced calcium
influx. The finding that ado does not increase cytosolic free
calcium is a new finding and suggests that ado does not lead to
a release of calcium from intracellular stores. Taken together
experimental evidence clearly argues against a role of calcium
as a second messenger of ado in inhibition of renin release from
renal juxtaglomerular cells.
Further candidates for second messengers in the control of
renin release are cyclic nucleotides such as cGMP and cAMP.
In a recent study we have obtained evidence that cGMP is also
involved in the intracellular control of renin release, in a way
that cGMP is a potent inhibitory signal [11]. It was obvious
therefore to test whether or not cGMP could be an intracellular
messenger that mediates inhibition of renin release by ado. And
indeed we found that ado led to an increase in cGMP1 (Fig. 4).
Three pieces of evidence were obtained to suggest that cGMP
could be the second messenger of ado to inhibit renin release
from juxtaglomerular cells. First, both the inhibition of renin
release and increase of cGMP, caused by ado are likely to be
mediated by A1-receptors, because both effects could be atten-
uated by theophylline and could be mimicked by CHA but not
by NECA (Figs. 2, 5). Second, the dose response curves of ado
for the increase in cGMP1 and for the decrease of renin release
were very similar (Figs. 1, 4). Third, the experimental data
obtained with ado matched with a correlation between cGMP1
and renin release that was obtained from independent experi-
ments (Fig. 6).
Finally a possible role of cAMP as the second messenger of
ado in the inhibition of renin release should be discussed. Cyclic
AMP is known as a stimulatory signal for renin release [9, 10].
Since A1-receptors have been found to be linked to the adenyl-
ate cyclase in an inhibitory fashion in a variety of cells [20] one
could speculate that ado impairs renin release by lowering the
intracellular concentration of cAMP due to an inhibition of the
adenylate cyclase. We determined the effect of ado on the
cellular level of cAMP in juxtaglomerular cells in the same
concentration range of ado in which inhibition of renin release
was observed, but we failed to detect any effect of ado on
cAMP1 (Fig. 4). Assuming that A1-receptors are inhibitorily
linked to the adenylate cyclase also in juxtaglomerular cells, it
might be remarkable that no decrease of cAMP1 in presence of
ado occurred. However, it has been shown for other cells that
A1-receptor occupancy does not affect basal cAMP,, but atten-
uates the rise in cAMP, induced by activators of the adenylate
cyclase [21]. At first sight the lack of effect of ado on cAMP
seems to argue against a second messenger role of cAMP for
ado in the inhibition of renin release. But from our measure-
ments we cannot rule out the possibility that ado causes locally
restricted decreases of cAMP that are crucial for the intracel-
lular control of renin release. Rossi, Churchill and Churchill
have recently reported that A1-receptor mediated inhibition of
renin release from renal cortical slices could be prevented by
pretreatment of the donor animals with pertussis toxin [22].
Since pertussis toxin is known to inactivate the inhibitory
guanine nucleotide binding regulatory protein of the adenylate
cyclase [23], they inferred from their finding that ado inhibits
renin release by the inhibition of the adenylate cyclase [22]. We
have also performed experiments with isolated juxtaglomerular
cells that were pretreated with pertussis toxin (islet activating
protein, lAP; 100 ng/ml) for 16 hours. We found that pretreat-
ment with lAP raised renin release two- to threefold from
control cells (that is, in the absence of ado) but did not alter
either cAMP1 or cGMP1. On the other hand, pretreatment with
lAP prevented both the inhibition of renin release and the rise
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Thus, although these findings fully confirm the results reported
by Rossi et al [22], they can be more easily explained if one
assumes that cGMP is the physiological antagonist of cAMP in
that it inhibits renin release from juxtaglomerular cells. In
summary we have presented evidence in this study that inhibi-
tion of renal renin release by adenosine is effected by a direct
interaction between ado and A1-receptors on juxtaglomerular
cells. Concerning the second messenger that mediates this
effect of ado, the experimental evidence points towards cGMP.
By which mechanism occupancy of A1-receptors leads to a rise
in cGMP3 in renal juxtaglomerular cells remains to be clarified.
In a recent study clear evidence was obtained that occupancy of
A1-receptors stimulates guanylate cyclase activity in vascular
smooth muscle cells [24]. In view of the fact that renal juxta-
glomerular cells are modified vascular smooth muscle cells [25]
one could speculate that stimulation of guanylate cyclase activ-
ity is also the mechanism by which ado raises cGMP1 in renal
juxtaglomerular cells.
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